Cure My Disease

Don't miss your cure!

 Log in / Sign up

New oral treatment shows promise for rare blood and kidney disorder

NCT ID NCT04889430

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This Phase 3 trial is testing whether an oral medication called iptacopan can safely and effectively treat atypical hemolytic uremic syndrome (aHUS), a rare disease that damages blood vessels and kidneys. The study involves about 50 adult patients who have not previously received specific complement inhibitor treatments. Researchers will measure improvements in blood counts, kidney function, and quality of life over 26 weeks and one year of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATYPICAL HEMOLYTIC-UREMIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Brigham and Womens Hospital

    Boston, Massachusetts, 02115, United States

  • Cleveland Clinic Foundation

    Cleveland, Ohio, 44195, United States

  • Comprehensive Transplant Ctr at OSU

    Columbus, Ohio, 43210, United States

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Georgetown University Lombardi Cancer Center

    Washington D.C., District of Columbia, 20007-2197, United States

  • Harbor-UCLA Medical Center .

    Torrance, California, 90502, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • Montefiore Medical Center .

    The Bronx, New York, 10461, United States

  • Novartis Investigative Site

    Fortaleza, Ceará, 60430 370, Brazil

  • Novartis Investigative Site

    Brasília, Federal District, 71635-580, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, 30150-221, Brazil

  • Novartis Investigative Site

    Recife, Pernambuco, 50740-900, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, 90035-074, Brazil

  • Novartis Investigative Site

    Botucatu, São Paulo, 18618-970, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 01327 001, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 04038-002, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 05403 000, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, 22270-060, Brazil

  • Novartis Investigative Site

    Salvador, 40323-010, Brazil

  • Novartis Investigative Site

    Nanjing, Jiangsu, 210009, China

  • Novartis Investigative Site

    Yantai, Shandong, 264000, China

  • Novartis Investigative Site

    Beijing, 100034, China

  • Novartis Investigative Site

    Beijing, 100191, China

  • Novartis Investigative Site

    Beijing, 100730, China

  • Novartis Investigative Site

    Shanghai, 200025, China

  • Novartis Investigative Site

    Ostrava, Poruba, 708 52, Czechia

  • Novartis Investigative Site

    Thiruvananthapuram, Kerala, 695011, India

  • Novartis Investigative Site

    Nagpur, Maharashtra, 440015, India

  • Novartis Investigative Site

    Pune, Maharashtra, 411011, India

  • Novartis Investigative Site

    Chandigarh, Punjab, 160012, India

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600006, India

  • Novartis Investigative Site

    Vellore, Tamil Nadu, 632 004, India

  • Novartis Investigative Site

    Hyderabad, Telangana, 500012, India

  • Novartis Investigative Site

    Lucknow, Uttar Pradesh, 226014, India

  • Novartis Investigative Site

    Iruma-gun, Saitama, 3500495, Japan

  • Novartis Investigative Site

    Izumo, Shimane, 693 8501, Japan

  • Novartis Investigative Site

    Bunkyo Ku, Tokyo, 1138655, Japan

  • Novartis Investigative Site

    Seoul, Korea, 03080, South Korea

  • Novartis Investigative Site

    Seoul, 06591, South Korea

  • Novartis Investigative Site

    Taichung, 40447, Taiwan

  • Novartis Investigative Site

    Taoyuan District, 33305, Taiwan

  • Rut Univ for Translational Med Scie

    New Brunswick, New Jersey, 08901, United States

  • St Barnabas Hospital

    Livingston, New Jersey, 07039, United States

  • USC Norris Cancer Center

    Los Angeles, California, 90033, United States

  • UT Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • Univ Cali Irvine ALS Neuromuscular

    Orange, California, 92868, United States

  • Univ of California at Los Angeles

    Los Angeles, California, 90095, United States

  • Univ of California at Sacramento

    Sacramento, California, 95817, United States

  • University Of Miami

    Miami, Florida, 33136, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45267-0585, United States

  • University of Minnesota

    Minneapolis, Minnesota, 55455, United States

  • Virginia Commonwealth University

    Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.

ATYPICAL HEMOLYTIC-UREMIC SYNDROME